Format

Send to

Choose Destination
PLoS One. 2014 Jan 24;9(1):e87179. doi: 10.1371/journal.pone.0087179. eCollection 2014.

Uridine prevents fenofibrate-induced fatty liver.

Author information

1
Nevada Cancer Institute, Las Vegas, Nevada, United States of America ; Desert Research Institute, Las Vegas, Nevada, United States of America.

Abstract

Uridine, a pyrimidine nucleoside, can modulate liver lipid metabolism although its specific acting targets have not been identified. Using mice with fenofibrate-induced fatty liver as a model system, the effects of uridine on liver lipid metabolism are examined. At a daily dosage of 400 mg/kg, fenofibrate treatment causes reduction of liver NAD(+)/NADH ratio, induces hyper-acetylation of peroxisomal bifunctional enzyme (ECHD) and acyl-CoA oxidase 1 (ACOX1), and induces excessive accumulation of long chain fatty acids (LCFA) and very long chain fatty acids (VLCFA). Uridine co-administration at a daily dosage of 400 mg/kg raises NAD(+)/NADH ratio, inhibits fenofibrate-induced hyper-acetylation of ECHD, ACOX1, and reduces accumulation of LCFA and VLCFA. Our data indicates a therapeutic potential for uridine co-administration to prevent fenofibrate-induced fatty liver.

PMID:
24475249
PMCID:
PMC3901748
DOI:
10.1371/journal.pone.0087179
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center